文献速递皮肤肿瘤

雀斑样黑素瘤治疗前免疫基因特征与咪喹莫特应答相关

A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response.
PubMed 文献 · J Invest Dermatol · 2019-09-30

研究评估27例雀斑样黑素瘤患者咪喹莫特治疗前后宿主免疫反应,患者每周用药5天共12周,16周时切除病灶行组织学评估。16例应答、11例未清除,应答者治疗前病灶PDL1蛋白表达升高并伴独特基因特征,含57个上调免疫基因,涉及抗原呈递、I型干扰素信号和T细胞活化。

要点

  • 雀斑样黑素瘤咪喹莫特完全应答率文献报道不一,需生物标志物筛选应答者。
  • 治疗前PDL1蛋白升高及57个免疫基因上调与16周组织学清除相关。
  • 该基因特征可能作为咪喹莫特治疗雀斑样黑素瘤的应答生物标志物。

核心结论

  • 雀斑样黑素瘤患者治疗前存在独特免疫基因特征,与咪喹莫特治疗后组织学清除相关。

研究设计与样本

  • 研究纳入27例雀斑样黑素瘤患者,均有咪喹莫特治疗前后配对标本。
  • 患者接受咪喹莫特每周5天共12周,16周时切除病灶行组织学评估。

主要发现

  • 27例中16例应答、11例未清除病灶。
  • 应答者治疗前病灶PDL1蛋白表达升高。
  • 应答者治疗前存在57个上调免疫基因,涉及抗原呈递、I型干扰素信号和T细胞活化。

关键数值与推荐

  • 咪喹莫特用法为每周5天、共12周,16周时行组织学评估。
  • 应答定义为16周时组织学清除雀斑样黑素瘤。

临床怎么用

  • 治疗前检测PDL1蛋白及免疫基因特征可能辅助筛选咪喹莫特应答者。

局限性

  • 样本量27例,应答者16例、未应答者11例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lentigo maligna (LM) is a common subtype of in situ melanoma on chronically sun-exposed skin, particularly the head and neck of older patients. Although surgery is the standard treatment, there is associated morbidity, and options such as imiquimod cream or radiotherapy may be used if surgery is refused or inappropriate. Complete response rates following imiquimod treatment are variable in the literature. The aim of this study was to evaluate the host immune response both before and following treatment with imiquimod to better identify likely responders. Paired pre- and post-imiquimod treatment specimens were available for 27 patients. Patients were treated with imiquimod 5 days per week for 12 weeks; at 16 weeks, lesions were excised for histological assessment. Of the 27 patients, 16 were responders and 11 failed to clear the disease. PDL1 protein expression was increased, accompanied by a unique gene signature in lesions from patients that subsequently histologically cleared LM by 16 weeks. This comprised 57 upregulated immune genes in signaling networks for antigen presentation, type I interferon signaling, and T-cell activation. This may represent an early responder group to imiquimod, and this unique gene signature potentially can be used as a biomarker of LM response to imiquimod.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Halse H, Caramia F, McLean CA, et al. A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response. J Invest Dermatol. 2019. PMID: 31580843. doi:10.1016/j.jid.2019.07.725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。